Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alfuzosin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D known ✓ | P25100 | 4/20 | 0.98 |
| ▸ | ADRA1A known ✓ | P35348 | 4/20 | 0.98 |
| ▸ | ADRA1B known ✓ | P35368 | 4/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.98 |
| ▸ | GLA | P06280 | 6/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.98 |
| ▸ | HPGD | P15428 | 6/20 | 0.98 |
| ▸ | GAA | P10253 | 5/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.98 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.98 |
| ▸ | ACHE | P22303 | 2/20 | 0.98 |
| ▸ | LMNA | P02545 | 2/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.98 |
| ▸ | DRD3 | P35462 | 1/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alfuzosin SCHEMBL179910 | 1.00 | KDM4E (0.98) | KDM4EGLAALDH1A1HPGDGAA | |
| Alfuzosin SCHEMBL4744369 | 1.00 | KDM4E (0.98) | KDM4EGLAALDH1A1HPGDGAA | |
| Alfuzosin SCHEMBL30690015 | 1.00 | KDM4E (0.98) | KDM4EGLAALDH1A1HPGDGAA | |
| Alfuzosin SCHEMBL29492949 | 1.00 | KDM4E (0.98) | KDM4EGLAALDH1A1HPGDGAA | |
| Alfuzosin SCHEMBL8115183 | 0.99 | KDM4E (0.97) | KDM4EGLAALDH1A1HPGDGAA | |
| Alfuzosin SCHEMBL1690751 | 0.99 | KDM4E (0.97) | KDM4EGLAALDH1A1HPGDGAA | |
| Alfuzosin SCHEMBL1690827 | 0.99 | KDM4E (0.97) | KDM4EGLAALDH1A1HPGDGAA | |
| Alfuzosin SCHEMBL8108037 | 0.99 | KDM4E (0.97) | KDM4EGLAALDH1A1HPGDGAA | |
| Alfuzosin SCHEMBL34477 | 0.99 | KDM4E (1.00) | KDM4EGLAALDH1A1HPGDGAA | |
| Alfuzosin SCHEMBL415972 | 0.99 | KDM4E (1.00) | KDM4EGLAALDH1A1HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240325380-A1 | COMPOSITIONS FOR OPIATE AND OPIOID PREVENTION AND REVERSAL, AND METHODS OF THEIR USE | TMTRx, Inc. (US) | 2024-10-03 | — | — | US | disclosed |
| US-20230091671-A1 | METHODS FOR OPIATE AND OPIOID OVERDOSE PREVENTION AND REVERSAL | TORRALVA MEDICAL THERAPEUTICS LLC (US) | 2023-03-23 | — | — | US | disclosed |
| US-20220160704-A2 | COMPOSITIONS FOR OPIATE AND OPIOID PREVENTION AND REVERSAL, AND METHODS OF THEIR USE | TORRALVA MEDICAL THERAPEUTICS LLC (US) | 2022-05-26 | — | — | US | disclosed |
| US-20100092556-A1 | ALFUZOSIN FORMULATIONS, METHODS OF MAKING, AND METHODS OF USE | MUTUAL PHARMACEUTICAL COMPANY, INC., A PENNSYLVANIA CORPORATION | 2010-04-15 | — | — | US | disclosed |
| WO-2009001369-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF ALFUZOSIN HYDROCHLORIDE | ALEMBIC LIMITED (IN) | 2008-12-31 | — | — | WO | disclosed |
| US-20080206338-A1 | CONTROLLED RELEASE FORMULATIONS OF AN ALPHA-ADRENERGIC RECEPTOR ANTAGONIST | AUROBINDO PHARMA LTD. (IN) | 2008-08-28 | — | — | US | disclosed |
| WO-2008102235-A1 | CONTROLLED RELEASE FORMULATIONS OF ALFUZOSIN | AUROBINDO PHARMA LIMITED (IN) | 2008-08-28 | — | — | WO | disclosed |
| US-20070049756-A1 | ALFUZOSIN HYDROCHLORIDE POLYMORPHS | DR. REDDY'S LABORATORIES, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20060062845-A1 | Alfuzosin tablets and synthesis | CIMEX PHARMA AG (CH) | 2006-03-23 | — | — | US | disclosed |
| US-20060062846-A1 | Alfuzosin tablets and synthesis | CIMEX PHARMA AG (CH) | 2006-03-23 | — | — | US | disclosed |
| EP-1637129-A1 | Composition comprising alfuzosin | Cimex Pharma AG (CH) | 2006-03-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230091671-A1 | METHODS FOR OPIATE AND OPIOID OVERDOSE PREVENTION AND REVERSAL | OPRM1, OPRD1, OPRK1 | ADRA1D 152/4885ADRA1A 181/4885ADRA1B 234/4885 |
| US-20220160704-A2 | COMPOSITIONS FOR OPIATE AND OPIOID PREVENTION AND REVERSAL, AND METHODS OF THEIR USE | OPRD1, OPRM1, CHRNA1 | ADRA1D 8/4885ADRA1A 9/4885ADRA1B 29/4885 |
| US-20070049756-A1 | ALFUZOSIN HYDROCHLORIDE POLYMORPHS | LPXN, EPM2A, UBE2V1 | ADRA1D 9/4885ADRA1A 6/4885ADRA1B 7/4885 |
| US-20240325380-A1 | COMPOSITIONS FOR OPIATE AND OPIOID PREVENTION AND REVERSAL, AND METHODS OF THEIR USE | OPRD1, OPRM1, CHRNA1 | ADRA1D 25/4885ADRA1A 16/4885ADRA1B 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.